Aldeyra Therapeutics reported a net loss of $22.3 million, or $1.40 per share, in 2017 compared with a net loss of $18.7 million, or $1.65 per share, in 2016, the company announced in a press release.
Research and development costs increased from $13.2 million in 2016 to $16.3 million in 2017, while general and administrative costs rose from $5.5 million to $6.2 million.
The spending increases were attributed to manufacturing, preclinical and clinical development costs, legal costs and personnel costs.
The company reported cash, cash equivalents and marketable securities of (Read more...)
Uncategorized